Prostate Cancer
Latest News
June 4th 2023
Talazoparib plus enzalutamide appears to improve the objective response rate vs enzalutamide plus placebo among patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair mutations in the phase 3 TALAPRO-2 study.
Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future
View More
Medical Crossfire®: Everything You Need to Know About the PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients with CRPC
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Medical Crossfire®: Everything You Need to Know About the PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
How Guidelines and Recent Clinical Trial Data Inform the Modern-Day Treatment of Advanced Prostate Cancer
View More
How Guidelines and Recent Clinical Trial Data Inform the Modern-Day Treatment of Advanced Prostate Cancer
View More
Medical Crossfire®: Key Questions on Sequencing, Radioligands, and Novel Emerging Approaches in CRPC
View More
Medical Crossfire®: Key Questions on Sequencing, Radioligands, and Novel Emerging Approaches in CRPC
View More
Show Me Your Care Plan! Developing Multidisciplinary Strategies to Optimize the First-Line Care of Patients with mRCC
View More
Oncology Town Hall™: Primary Investigators Present Key Abstracts in Genitourinary Malignancies from Paris
View More
Oncology Town Hall™: Primary Investigators Present Key Abstracts in Genitourinary Malignancies from Paris
View More
Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings
View More
Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings
View More
Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
